article thumbnail

JAPAC Drug Development: Navigating Safety & Regulatory Requirements

HIT Consultant

In fact, in 2018, 80% of all biopharma pipeline projects in JAPAC were EBPs, accounting for 75% of the total clinical trial volume in the region. They are also in communication with the sponsor, who is the MAH of the active pharmaceutical ingredient. In comparison to Japan, China has fewer distinctions.

article thumbnail

Newsletter, November 2022

Patient Safety Movement

Breanne Everett , CEO and President at Orpyx Medical, discusses the different types of diabetes, comorbidities associated with the disease, and the prevention and management of diabetes-related complications to improve patient quality of life and reduce healthcare costs. It considers patient safety integral to all these priorities.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How to Market to Doctors, Physicians, and Other Health Care Professionals

Healthcare Success

Generally speaking, doctors control large sums of money both professionally and personally, making them a highly desirable target audience for pharmaceutical companies, device and supply companies, SaaS, and even those outside the healthcare industry, like real estate brokers and investment advisors.

Doctors 145
article thumbnail

5 Key Challenges Preventing Innovation in Digital Health

HIT Consultant

Data privacy and security Within pharmaceutical , hospital, clinic and other healthcare settings, there is a need to balance the requirements of data protection and security with the need for innovation such as real-time alerting, predictive analysis, and telemedicine. million patients affected by data breaches in 2021 alone.

article thumbnail

The Economic Contours of the Change Healthcare Cyber Attack: Taking Stock So Far

Health Populi

The cost of patient data spillage : We won’t know the estimate for this line-item for some time, but we must keep it in our accounting as a key line-item on patients’ minds and, potentially, in pocketbooks. A future hit on providers’ credit ratings?

article thumbnail

A Precautionary Approach to Touch in Psychedelic-Assisted Therapy

Bill Of Health

Importantly, current processes of accountability for both training standards and practice standards in this area are nascent. In the emerging psychedelics industry, the institutions and actors that require oversight and regulation are positioning themselves as regulators. Mithoefer & Haden ).

article thumbnail

White vs. Brown vs. Clear Bagging

Healthcare ECONOMIST

the three biggest PBMs aligned with payers –CVS/Aetna, Optum/UnitedHealthcare, and Express Scripts/Cigna — accounted for 77% of all prescription claims.36,37 Key criticisms of white and brown bagging are: Patient safety. Part of the reason for increased ‘bagging’ policies has to do with industry consolidation.